DDInter790 DDInter636
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) resembles {v} (Compound) Bumetanide
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Niacin
Niacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) binds {v} (Gene) SLC22A11
SLC22A11 {u} (Gene) is bound by {v} (Compound) Conjugated estrogens
Conjugated estrogens {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is palliated by {v} (Compound) Amlodipine
Amlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Etacrynic acid
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) resembles Bumetanide (Compound) and Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Niacin (Compound) and Niacin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) binds SLC22A11 (Gene) and SLC22A11 (Gene) is bound by Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is palliated by Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Furosemide (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Etacrynic acid (Compound) and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin